- Home/
- Article /
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Full Author : ['Nowicki, M', 'Rychlik, I', 'Haller, H', 'Warren, M', 'Suchower, L', 'Gause-Nilsson, I', 'Schutzer, K-M']
Journal Title : International journal of clinical practice
Chapter : Section10, Section25, Section3, Section4, Section8, Section9
Journal Year : 2011
OBJECTIVE: Therapeutic options are limited for diabetes patients with renal disease. This report presents 52-week results from a study assessing the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus (T2DM) and renal im.....
Keywords : ['type diabetes mellitus', 'randomised control efficacy', 'dipeptidyl inhibitor saxagliptin', 'safety study', 'renal impairment', 'longterm treatment', 'patient']